JP2024537192A - がんを処置するためのｗｎｔシグナル伝達を増強するための組成物および方法 - Google Patents

がんを処置するためのｗｎｔシグナル伝達を増強するための組成物および方法 Download PDF

Info

Publication number
JP2024537192A
JP2024537192A JP2024520926A JP2024520926A JP2024537192A JP 2024537192 A JP2024537192 A JP 2024537192A JP 2024520926 A JP2024520926 A JP 2024520926A JP 2024520926 A JP2024520926 A JP 2024520926A JP 2024537192 A JP2024537192 A JP 2024537192A
Authority
JP
Japan
Prior art keywords
cancer
gsk
subject
inhibitor
wnt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537192A5 (enExample
Inventor
ジョージ エング，
オメル イルマズ，
ジョナサン ブレイバーマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2024537192A publication Critical patent/JP2024537192A/ja
Publication of JP2024537192A5 publication Critical patent/JP2024537192A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024520926A 2021-10-07 2022-10-07 がんを処置するためのｗｎｔシグナル伝達を増強するための組成物および方法 Pending JP2024537192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253380P 2021-10-07 2021-10-07
US63/253,380 2021-10-07
PCT/US2022/077746 WO2023060226A1 (en) 2021-10-07 2022-10-07 Compositions and methods for enhancing wnt signaling for treating cancer

Publications (2)

Publication Number Publication Date
JP2024537192A true JP2024537192A (ja) 2024-10-10
JP2024537192A5 JP2024537192A5 (enExample) 2025-10-17

Family

ID=83978871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520926A Pending JP2024537192A (ja) 2021-10-07 2022-10-07 がんを処置するためのｗｎｔシグナル伝達を増強するための組成物および方法

Country Status (8)

Country Link
US (2) US12440497B2 (enExample)
EP (1) EP4412614A1 (enExample)
JP (1) JP2024537192A (enExample)
CN (1) CN118338903A (enExample)
AU (1) AU2022361519A1 (enExample)
CA (1) CA3233974A1 (enExample)
IL (1) IL311934A (enExample)
WO (1) WO2023060226A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106408A1 (en) * 2007-02-27 2008-09-04 Cedars-Sinai Medical Center Treatment of cancer with bio and chemotherapy
JPWO2006073202A1 (ja) * 2005-01-04 2008-08-07 国立大学法人金沢大学 ＧＳＫ３β阻害効果に基づくがんの抑制および抗がん剤の評価方法
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP2016538342A (ja) * 2013-11-18 2016-12-08 イエール ユニバーシティ トランスポゾンを使用する組成物および方法
US20230241000A1 (en) * 2020-06-30 2023-08-03 The Regents Of The University Of California Gsk3 inhibitor-loaded nano formulations as a cancer immunotherapeutic

Also Published As

Publication number Publication date
IL311934A (en) 2024-06-01
CA3233974A1 (en) 2023-04-13
US12440497B2 (en) 2025-10-14
CN118338903A (zh) 2024-07-12
US20260091038A1 (en) 2026-04-02
WO2023060226A1 (en) 2023-04-13
EP4412614A1 (en) 2024-08-14
US20230190767A1 (en) 2023-06-22
AU2022361519A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
US11918686B2 (en) Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
Ji et al. Designing liposomes to suppress extracellular matrix expression to enhance drug penetration and pancreatic tumor therapy
Zhang et al. EGFP–EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma
AU2017286733B2 (en) Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
Gu et al. Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer
Yuan et al. Transforming cancer-associated fibroblast barrier into drug depots to boost chemo-immunotherapy in “shooting fish in a barrel” pattern
Bai et al. Homotypic targeted photosensitive nanointerferer for tumor cell cycle arrest to boost tumor photoimmunotherapy
CN101674810A (zh) 针对癌细胞和癌相关成纤维细胞的靶向剂
CN106470681A (zh) 超分子组合治疗药物
Chen et al. Activated T cell-derived exosomes for targeted delivery of AXL-siRNA loaded paclitaxel-poly-L-lysine prodrug to overcome drug resistance in triple-negative breast cancer
WO2017095751A1 (en) Compositions and methods for modulating cancer cell metabolism
Conte et al. Multimodal therapies against pancreatic ductal adenocarcinoma: a review on synergistic approaches toward ultimate nanomedicine treatments
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
TW201217361A (en) Method of treating abnormal cell growth
Luo et al. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor
Dreaden et al. RNA‐peptide nanoplexes drug DNA damage pathways in high‐grade serous ovarian tumors
Tian et al. Extracellular vesicles delivered rapamycin to improve the tumor microenvironment and enhance hepatocellular carcinoma immunotherapy
JP2019505582A (ja) タキサンのカチオン性リポソーム製剤、タキサンの非リポソーム製剤およびさらなる活性剤の併用を用いた乳癌の治療
US12440497B2 (en) Compositions and methods for enhancing Wnt signaling for treating cancer
Meng et al. Effect of chitosan based glycolipid-like nanocarrier in prevention of developing acquired drug resistance in tri-cycle treatment of breast cancer
US20230310504A1 (en) Platelet membrane coated nanoparticles and uses thereof
Xing et al. Engineered nanomaterials for tumor immune microenvironment modulation in cancer immunotherapy
Ma et al. Synergistic nanobubble-mediated sonodynamic therapy and MicroRNA immunotherapy suppresses hepatocellular carcinoma
WO2023081514A1 (en) Cxcr4 antagonist loaded liposomes and silicasomes
US20250312411A1 (en) Treatment of Multi-Drug-Resistant Cancers Using Nanoparticulate Drug Delivery Vehicles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251007